Science

Very excited to announce that we’ve dosed our first patient with our latest next-gen cancer immunotherapy drug which is broadly applicable to most solid tumors!  

We started working on this one in 2022.  It’s really cool to see how quickly a drug can go from an idea into the clinic.

Very excited to announce that we’ve dosed our first patient with our latest next-gen cancer immunotherapy drug which is broadly applicable to most solid tumors!  

We started working on this one in 2022.  It’s really cool to see how quickly a drug can go from an idea into the clinic.

https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx

Scientist 🧬, dog lover 🐶, amateur photographer 📸, crypto enthusiast, Cat Town Farcaster Community Leader

Researcher at MIT Media Lab | Creating futures | https://cyrus.website/info

Thanks!  Yeah, very promising and also a big test for our platform as EGFR is expressed widely in the body.

69 $TIPN